Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06271733 · ClinicalTrials.gov registry record · NA

TMS for Veterans Attending a 2-week Intensive Outpatient Program for PTSD

A NA study of PTSD, sponsored by Rush University Medical Center.

Completed
Registry status
NA
Development phase
6
Enrollment target
1
Study location

NCT06271733 is a NA study of PTSD that has completed, run by Rush University Medical Center. The registered enrollment target is 6 participants, below the 302-participant average among 154 other PTSD trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06271733, a NA study of PTSD, has completed, sponsored by Rush University Medical Center.

COMPLETED
Registry status
NA
Development phase
6 participants
Enrollment target
1
Study location

Study Summary

The goal of this study is to determine whether complementing regular intensive PTSD treatment with intermittent theta burst stimulation (iTBS) applied to the right dorsolateral prefrontal cortex (DLPFC) can improve treatment response for individuals attending a 2-week intensive outpatient program (IOP) for PTSD.

Conditions Studied

Interventions

  • DEVICE TMS

Study Locations (1)

Illinois

  • Rush University Medical Center - Chicago

Trial Details

FieldValue
Enrollment Target 6 participants
Start Date 2022-01-11
Est. Completion 2025-10-27
Phase NA

Sponsor

Rush University Medical Center

320 total trials

What the Registry Record Tells You About NCT06271733

The ClinicalTrials.gov registry entry for NCT06271733 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 302-participant average among 154 other PTSD trials with a reported enrollment target (98% lower). The listed sponsor is Rush University Medical Center, which has 320 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with PTSD appearing as the primary indexed condition, and to 1 intervention - of which TMS is the first listed.

NCT06271733 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.

Frequently Asked Questions

What is clinical trial NCT06271733 about?

NCT06271733 is a clinical study titled "TMS for Veterans Attending a 2-week Intensive Outpatient Program for PTSD". The goal of this study is to determine whether complementing regular intensive PTSD treatment with intermittent theta burst stimulation (iTBS) applied to the right dorsolateral prefrontal cortex (DLPFC) can improve treatment response for individuals attending a 2-week intensive outpatient program (I...

What is the current status of trial NCT06271733?

This trial is currently completed. It is a NA study. The enrollment target is 6 participants. The study started on 2022-01-11. Estimated completion is 2025-10-27.

What conditions does trial NCT06271733 study?

This clinical trial studies the following conditions: PTSD.

What interventions are being tested in trial NCT06271733?

The interventions under investigation include: TMS (DEVICE).

Who is sponsoring clinical trial NCT06271733?

This trial is sponsored by Rush University Medical Center, which has 320 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06271733 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for PTSD

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.